• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lorazepam not superior to diazepam for pediatric status epilepticus

byJohn PrendergassandBrittany Hasty, MD
April 24, 2014
in Chronic Disease, Emergency, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Lorazepam did not significantly improve odds of status epilepticus cessation compared to diazepam. 

2. Diazepam and lorazepam groups demonstrated similar rates of required assisted ventilation.    

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Diazepam is one of the mainstays of treatment for status epilepticus in the pediatric population. However, a number of studies have shown lorazepam to be a more efficacious treatment for status epilepticus. The results of these studies are questionable due to small sample sizes and a lack of generalizability. This randomized control study sought to determine whether lorazepam is safer and more efficacious when compared to diazepam for the treatment of status epilepticus.

The researchers concluded that lorazepam was not more efficacious than diazepam for the treatment of pediatric status epilepticus; however, lorazepam was more likely to cause sedation Because the study was designed as a superiority trial as opposed to a noninferiority trial, it is important to note that diazepam and lorazepam cannot be concluded to be equivalent. This study is aided by its randomized active-control trial design and protocol for standardized drug administration. Limitations include the unpredictable nature of the emergency room leading to protocol deviations and electroencephalogram monitoring was not used.

Click to read the study in JAMA

RELATED REPORTS

New prognostication tool predicts neurological deficits and long-term survival in patients with status epilepticus

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

Quick Take: Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT)

Relevant Reading: Intramuscular vs. Intravenous Therapy for Prehospital Status Epilepticus

In-Depth [randomized clinical trial]: This study randomized 273 (140 on diazepam and 133 on lorazepam) patients at 11 pediatric hospitals in the United States. Status epilepticus ceased within 10 minutes, without recurring within 30 minutes, in 101(72.1%)  diazepam patients and 97(72.9%) lorazepam patients (absolute efficacy difference, 0.8%; 95%CI, -11.4% – 9.8%). Assisted ventilation was required in 16.0% of the diazepam group and 17.6% of the lorazepam group. Rates of recurrent generalized convulsions within 60 minutes were 10.9% for diazepam and 10.3% for lorazepam. The mean time to termination of status epilepticus was 2.5 minutes in the diazepam group and 2.0 minutes in the lorazepam group (p= .80). There was a stasticially significant difference in the incidence of sedation occurring in 50% of diazepam patients and 66.9% of lorazepam patients (absolute risk difference 16.9%; 95% CI 6.1%- 27.7%).

More from this author: Reducing surgical complications may increase costs,Protected sleep periods improve intern alertness and sleep duration,ADHD medication decreases rates of criminality in ADHD patients,Low dose aspirin shows net clinical benefit in patients with first unprovoked venous thromboembolism, Rare TREM-2 mutation implicated in Alzheimer’s Disease

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

 

Tags: diazepamLorazepamstatus epilepticus
Previous Post

Vitamin D supplementation does not reduce risk of falls

Next Post

Neuroendocrine tumor marker pancreastatin may be predictive of survival

RelatedReports

Neurology

New prognostication tool predicts neurological deficits and long-term survival in patients with status epilepticus

April 15, 2022
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication
StudyGraphics

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

December 29, 2021
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Quick Take: Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT)

April 28, 2019
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Weekly Rewinds

2 Minute Medicine Rewind April 22, 2019

April 26, 2019
Next Post
Neuroendocrine tumor marker pancreastatin may be predictive of survival

Neuroendocrine tumor marker pancreastatin may be predictive of survival

Recurrent violence in post-conflict communities linked to increased mental disorders

Recurrent violence in post-conflict communities linked to increased mental disorders

Whole-lung irradiation associated with greater risk of breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.